国: オランダ
言語: 英語
ソース: HMA (Heads of Medicines Agencies)
porcine reproductive and respiratory syndrome virus inactivated 2.5 log10 IF Units
Merial
QI09AA05
Emulsion for injection
Porcine reproductive and respiratory syndrome (PRRS) virus
Pigs
2010-02-18
Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 2 February 2010 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Progressis. Emulsion for injection for pigs (sows and gilts) Name in Austria: “Progressis - Emulsion zur Injektion für Schweine“ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2-ml dose of vaccine contains: ACTIVE SUBSTANCE : Inactivated Porcine Reproductive and Respiratory Syndrome (PRRS) virus, P120 strain ..................................................................................................... 2.5 log 10 IF* units. *IF units: ImmunoFluorescence antibody titre obtained after 2 inje ctions in pigs under specific laboratory conditions. ADJUVANT: O/w oily excipient (containing hydrogenated polyisobutene as adjuvant) .................. q.s. 1 dose of 2 ml. EXCIPIENT(S): For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Emulsion for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs (sows and gilts). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Reduction of the reproductive disorders caused by Porcine Reproductive and Respiratory Syndrome virus (European strain) in a contaminated environment: vaccination reduces the number of early farrowings and the number of still-births. 4.3 CONTRAINDICATIONS None 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES In PRRS infected herds, viral infection is heterogeneous and varies over time. In such context, the implementation of a vaccination program is a tool to improve the reproductive parameters 完全なドキュメントを読む